Page 221 - Small Animal Internal Medicine, 6th Edition
P. 221

CHAPTER 10   Pulmonary Hypertension and Heartworm Disease   193


            phosphodiesterase-5 inhibitors (sildenafil and tadalafil).   Canada; the disease is prevalent in other regions of the world
            These drugs decrease the inactivation of cyclic guanosine   as well. Infection with Dirofilaria immitis causes a spectrum
  VetBooks.ir  monophosphate (GMP), a second messenger of the nitric   of disease ranging from mild, subclinical changes to severe
                                                                 pulmonary disease and secondary right-sided CHF. Dogs
            oxide pathway, leading to vasodilation. Phosphodiesterase-5
            inhibitors are relatively specific for the pulmonary vascula-
                                                                 cats also are affected by HWD, they are more resistant to
            ture and thus act as selective pulmonary vasodilators. Treat-  and other canids are the preferred host species. Although
            ment with sildenafil can improve clinical signs and quality   infection than dogs. The overall prevalence of mature HW
            of life in dogs with severe PAH, although effects on echo-  infection in cats in the United States is 0.4%, and regionally
            cardiographically estimated pulmonary arterial pressures   is thought to be 5% to 15% of that in dogs in the same geo-
            are variable. Dose adjustments typically are made based   graphic area. However, exposure to and subsequent clear-
            on clinical status. Adverse effects are uncommon but can   ance of larvae by host reactions is estimated to be much more
            include cutaneous flushing, hypotension, and nasal conges-  common.
            tion. Other therapies used in people with PAH (endothe-
            lin  receptor  antagonists,  prostacyclin  analogs,  and nitric   HEARTWORM LIFE CYCLE
            oxide substrates) usually are cost-prohibitive for veterinary   The HW  (D. immitis) is transmitted by various species of
            patients, and many require delivery via inhalation or con-  mosquitoes, which act as its obligate intermediate host. A
            tinuous intravenous (IV) infusion.                   mosquito initially ingests the microfilariae, or first-stage
              Management of patients with PAH also involves exercise   larvae (L 1 ), which circulate in the blood of an infected host
            restriction and treatment of the underlying disease (if identi-  animal. The L 1  develops into an L 2  and then enters the infec-
            fied). Treatment of HWD is discussed later in this chapter;   tive L 3  stage within the mosquito over a period of approxi-
            treatment of  pulmonary  thromboembolic  disease is  dis-  mately 2 to 2.5 weeks. Symbiotic bacteria of the genus
            cussed in Chapter 12; and treatment of chronic bronchopul-  Wolbachia are important for larval development within the
            monary disease is discussed in Chapter 21.           mosquito. Infective larvae enter the new host when the mos-
              For dogs with postcapillary PAH secondary to left-sided   quito takes another blood meal. L 3  larvae migrate subcutane-
            heart  disease,  treatment  focuses  on  decreasing  left  atrial   ously within the new host, molting into an L 4  stage within 9
            (and thus pulmonary venous) pressures. This generally   to 12 days, and then entering the L 5  (final) stage by 2 to 3
            involves balanced systemic vasodilation with pimobendan   months postinfection. The juvenile L 5  worms enter the vas-
            (a phosphodiesterase-III inhibitor) and an angiotensin-  culature within about 100 days of infection, where they
            converting enzyme inhibitor (ACEI), as well as preload   migrate preferentially to the peripheral pulmonary arteries
            reduction with diuretics (furosemide). Further systemic   of the caudal lung lobes. It takes at least 5 to 6 and usually
            arterial vasodilation (afterload reduction) with amlodipine   between 7 and 9 months before these worms develop into
            also can be considered; amlodipine has some vasodilatory   mature adults; after mating, gravid females release microfi-
            activity in pulmonary arterioles as well. If clinically rele-  lariae (L 1 ) and the infection becomes patent. Mature male
            vant PAH persists despite therapy for pulmonary venous   worms grow to approximately 15 to 18 cm, whereas adult
            hypertension and CHF, sildenafil can be used as adjunctive   females can reach 25 to 30 cm in length. Adult worms can
            therapy. Dogs with right-sided CHF secondary to PAH (cor   survive for 5 to 7 years in dogs. HW transmission is limited
            pulmonale) are managed similarly to those with other causes   by climate. An average daily temperature of greater than 64°
            of CHF (furosemide, pimobendan, ACEI, dietary sodium   F for about a month is necessary for the L 1  larvae to mature
            restriction) with the addition of sildenafil.        within a mosquito to the infective stage. HW transmission
              Prognosis  for  dogs with PAH varies with underly-  peaks during July and August in temperate regions of the
            ing disease. Other  than HWD, most  causes of PAH  are   Northern Hemisphere.
            advanced and incurable, and pulmonary vascular remodel-  Microfilariae passed to another animal by blood trans-
            ing is irreversible. The prognosis for dogs with severe PAH   fusion or across the placenta do not develop into adult
            generally is poor, with median survival times between 3   worms because the mosquito host is required to complete
            and 6 months; treatment with sildenafil improves survival,   the parasite’s life cycle. Therefore puppies younger than
            with one study reporting nearly 75% survival at 1 year    6 months of age that have circulating microfilariae most
            postdiagnosis.                                       likely received them transplacentally and do not have patent
                                                                 HWD. Survival of microfilaria for up to 30 months has
                                                                 been reported.
            HEARTWORM DISEASE                                      HW development proceeds more slowly in the cat, which
                                                                 is not the natural host, and infection does not become
            HWD is an important cause of PAH in regions where the   patent (mature) until at least 7 to 8 months postinfection.
            disease is endemic. HW infection is widespread throughout   Adult worms can live for 3 to 4 years in cats. Microfilar-
            the United States, especially along the Eastern and Gulf   iae are evident only in a minority of cats. Nevertheless,
            coasts and in the Mississippi River Valley. The infection rate   infection with L 3  through immature L 5  can cause sub-
            in unprotected dogs can be up to 45% or higher in some   stantial pulmonary disease as the host attempts to reject
            areas. Sporadic cases occur in other areas of the country and   the parasites.
   216   217   218   219   220   221   222   223   224   225   226